ArticleBMC infectious diseases2019
Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed.
- Review
- Carbapenem-Resistant Acinetobacter baumannii: Resistance, Virulence, and Possible Dissemination Between Different Hospitals in Western Iran.Biochemical genetics · 2026Article
- Comparative Population Genomics and Machine Learning Reveal a Distinct Regional Genomic Fingerprint of Middle EasternMicroorganisms · 2026Article
- Prevalence and associations of antibiotic resistance and biofilm formation with molecular determinants in clinical Acinetobacter baumannii isolates.Scientific reports · 2026Article
- Isolation, characterization, and genomic analysis of a novel lytic bacteriophage with potent antibiofilm activity against multidrug-resistant Acinetobacter baumannii.BMC microbiology · 2026Article
- Antibiotic Resistance and Biofilm Gene Distribution in Colistin-Resistant Acinetobacter baumannii.MicrobiologyOpen · 2026Article
- Genomic and phenotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from patients and trolleys and their potential connections in an intensive care unit.BMC microbiology · 2026Observational
- The dual role of the microbiome in chronic wound management.Cell communication and signaling : CCS · 2026Review
- Article
- Genomic and phenotypic analysis of multidrug-resistant Acinetobacter baumannii focusing on efflux pump activity and biofilm-associated genes.Molecular biology reports · 2026Article
- Harnessing the power of ferulic acid as a dual-action strategy against biofilm-forming extensively drug-resistant Acinetobacter baumannii isolated from cancer patients: in vitro and in vivo study.BMC microbiology · 2026Article
- Genomic Epidemiology of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Clonal patient-to-patient spread is associated with multidrug-resistantFrontiers in medicine · 2026Article
- Article
- Biofilm Formation in ClinicalBioMed research international · 2026Article
- A newly identified sequence type: genomic and pathogenic profiling of the highly virulentFrontiers in cellular and infection microbiology · 2026Article
- Genomic characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Acinetobacter baumannii-rare virulence factors and pathogenesis: the impact of biofilm associated protein (Bap), outer membrane vesicles, and iron acquisition system.Archives of microbiology · 2025Review
- Agglutination of Escherichia coli, Clostridium perfringens, and Salmonella enterica through competitive exclusion using potassium chloride with gum arabic.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Characterization of carbapenem-resistant biofilm forming Acinetobacter baumannii isolates from clinical and surveillance samples.Scientific reports · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNosocomial infections and persistence of multidrug resistant biofilm forming Acinetobacter baumannii in hospitals has made it as a serious problem in healthcare settings worldwide.
methodsA total of 100 A. baumannii clinical isolates from immunocompromised patients hospitalized in ICU were investigated for biofilm formation, the presence of biofilm related genes (bap, ompA, csuE, fimH, epsA, bla
resultsAll isolates were resistant to three or more categories of antibiotics and considered as multidrug resistant (MDR). A total of 32 isolates were resistant to all tested antibiotics and 91% were extensively drug-resistance (XDR). All isolates were able to produce biofilm and 58% of isolates showed strong ability to biofilm formation. All strong biofilm forming A. baumannii isolates were XDR. All A. baumannii isolates carried at least one biofilm related gene. The most prevalent gene was csuE (100%), followed by pgaB (98%), epsA and ptk (95%), bfmS (92%) and ompA (81%). 98% of isolates carried more than 4 biofilm related genes, simultaneously. Class I integron (67%) was more frequent in comparison with class II (10%) (P < 0.05). The REP-PCR patterns were classified as 8 types (A-H) and 21 subtypes. The A1 (23%) and C1 (15%) clusters were the most prevalent among A. baumannii isolates (P < 0.05). According to the REP-PCR patterns, 23% of all isolates had a clonal relatedness.
conclusionOur study revealed the high frequency of biofilm forming XDR A. baumannii in ICU patients, with a high prevalence of biofilm related genes of csuE and pgaB. It seems that the appropriate surveillance and control measures are essential to prevent the emergence and transmission of XDR A. baumannii in our country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.